GPRC5B

Across TCGA pan-cancer cohorts, GPRC5B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GPRC5B data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GPRC5B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GPRC5B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LAML, and THCA are the cancer types where GPRC5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.442	.027	16	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
THCA	DFS	Median	All	0.178	0.842	.010	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GPRC5B–UCEC (DFS)

Open the UCEC breakdown →